List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1678408/publications.pdf Version: 2024-02-01

		117625	53230
99	9,477	34	85
papers	citations	h-index	g-index
117	117	117	15523
all docs	docs citations	times ranked	citing authors

HELEN Y CHIL

#	Article	IF	CITATIONS
1	Diagnostic Accuracy of an At-Home, Rapid Self-test for Influenza: Prospective Comparative Accuracy Study. JMIR Public Health and Surveillance, 2022, 8, e28268.	2.6	5
2	Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 – King County, Washington. Vaccine, 2022, 40, 122-132.	3.8	19
3	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell, 2022, 185, 872-880.e3.	28.9	165
4	Phylogenomics of SARS-CoV-2 in Emergency Shelters for People Experiencing Homelessness. Journal of Infectious Diseases, 2022, , .	4.0	3
5	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. ELife, 2022, 11, .	6.0	19
6	Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022, 185, 881-895.e20.	28.9	605
7	Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial. Cell Reports, 2022, 38, 110337.	6.4	3
8	Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. Clinical Infectious Diseases, 2022, , .	5.8	0
9	Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. Journal of Infectious Diseases, 2022, , .	4.0	4
10	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS Pathogens, 2022, 18, e1010248.	4.7	48
11	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	27.8	917
12	Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell, 2022, 185, 1588-1601.e14.	28.9	137
13	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. PLoS Pathogens, 2022, 18, e1010155.	4.7	6
14	The Clinical and Genomic Epidemiology of Rhinovirus in Homeless Shelters—King County, Washington. Journal of Infectious Diseases, 2022, 226, S304-S314.	4.0	6
15	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS Pathogens, 2022, 18, e1010592.	4.7	13
16	Transplacental Respiratory Syncytial Virus and Influenza Virus Antibody Transfer in Alaska Native and Seattle Mother–Infant Pairs. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 230-236.	1.3	5
17	Epidemiology of Respiratory Syncytial Virus Across Five Influenza Seasons Among Adults and Children One Year of Age and Older—Washington State, 2011/2012–2015/2016. Journal of Infectious Diseases, 2021, 223, 147-156.	4.0	10
18	Human Metapneumovirus Infection and Genotyping of Infants in Rural Nepal. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 408-416.	1.3	7

#	Article	IF	CITATIONS
19	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 197-205.	4.0	216
20	Incidence of Medically Attended Acute Respiratory Illnesses Due to Respiratory Viruses Across the Life Course During the 2018/19 Influenza Season. Clinical Infectious Diseases, 2021, 73, 802-807.	5.8	8
21	Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Network Open, 2021, 4, e210830.	5.9	663
22	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. Scientific Reports, 2021, 11, 4290.	3.3	22
23	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight, 2021, 6, .	5.0	39
24	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host and Microbe, 2021, 29, 463-476.e6.	11.0	1,054
25	Effects of weather-related social distancing on city-scale transmission of respiratory viruses: a retrospective cohort study. BMC Infectious Diseases, 2021, 21, 335.	2.9	14
26	Evaluating Specimen Quality and Results from a Community-Wide, Home-Based Respiratory Surveillance Study. Journal of Clinical Microbiology, 2021, 59, .	3.9	17
27	High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. Cell, 2021, 184, 2927-2938.e11.	28.9	35
28	One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. ImmunoHorizons, 2021, 5, 322-335.	1.8	19
29	Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019–April 2020. PLoS ONE, 2021, 16, e0252235.	2.5	2
30	Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State. Science Translational Medicine, 2021, 13, .	12.4	58
31	Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. Cell Reports, 2021, 35, 109164.	6.4	44
32	A remote householdâ€based approach to influenza selfâ€ŧesting and antiviral treatment. Influenza and Other Respiratory Viruses, 2021, 15, 469-477.	3.4	7
33	Evaluating an app-guided self-test for influenza: lessons learned for improving the feasibility of study designs to evaluate self-tests for respiratory viruses. BMC Infectious Diseases, 2021, 21, 617.	2.9	3
34	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Science Translational Medicine, 2021, 13, .	12.4	198
35	Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection in the Community Setting. JAMA Pediatrics, 2021, 175, e212025.	6.2	80
36	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Reports, 2021, 36, 109353.	6.4	95

#	Article	IF	CITATIONS
37	Factors and Challenges in Understanding SARS-CoV-2 RNA Levels, Symptoms, and Transmissibility—Reply. JAMA Pediatrics, 2021, 175, 1293-1294.	6.2	0
38	SARS-CoV-2 Epidemiology on a Public University Campus in Washington State. Open Forum Infectious Diseases, 2021, 8, ofab464.	0.9	12
39	Dynamics of breast milk antibody titer in the six months following SARS-CoV-2 infection. Journal of Clinical Virology, 2021, 142, 104916.	3.1	15
40	Remote Household Observation for Noninfluenza Respiratory Viral Illness. Clinical Infectious Diseases, 2021, 73, e4411-e4418.	5.8	17
41	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. , 2021, 9, e003428.		11
42	A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. Science Advances, 2021, 7, eabj0274.	10.3	28
43	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science, 2021, 374, 1621-1626.	12.6	232
44	Primary and Repeated Respiratory Viral Infections Among Infants in Rural Nepal. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 21-29.	1.3	11
45	Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S577-S583.	4.0	231
46	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science, 2020, 370, .	12.6	511
47	The Seattle Flu Study: a multiarm community-based prospective study protocol for assessing influenza prevalence, transmission and genomic epidemiology. BMJ Open, 2020, 10, e037295.	1.9	25
48	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity, 2020, 53, 524-532.e4.	14.3	334
49	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	28.9	420
50	Cross-Sectional Prevalence of SARS-CoV-2 Among Skilled Nursing Facility Employees and Residents Across Facilities in Seattle. Journal of General Internal Medicine, 2020, 35, 3302-3307.	2.6	11
51	Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Nature Communications, 2020, 11, 4378.	12.8	63
52	Nausea, vomiting and poor appetite during pregnancy and adverse birth outcomes in rural Nepal: an observational cohort study. BMC Pregnancy and Childbirth, 2020, 20, 545.	2.4	8
53	Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection. JAMA Network Open, 2020, 3, e2016382.	5.9	104
54	Assessment of indirect protection from maternal influenza immunization among non-vaccinated household family members in a randomized controlled trial in Sarlahi, Nepal. Vaccine, 2020, 38, 6826-6831.	3.8	0

#	Article	IF	CITATIONS
55	Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial. Trials, 2020, 21, 956.	1.6	7
56	Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses, 2020, 12, 513.	3.3	641
57	Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity, 2020, 53, 98-105.e5.	14.3	376
58	Respiratory viral coinfection in a birth cohort of infants in rural Nepal. Influenza and Other Respiratory Viruses, 2020, 14, 739-746.	3.4	12
59	Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform. New England Journal of Medicine, 2020, 383, 185-187.	27.0	97
60	Respiratory syncytial virus and influenza hospitalizations in Alaska native adults. Journal of Clinical Virology, 2020, 127, 104347.	3.1	6
61	Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. Clinical Infectious Diseases, 2020, 71, 2167-2173.	5.8	95
62	Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. Journal of Infectious Diseases, 2019, 219, 59-67.	4.0	42
63	Phylogenetic characterization of rhinoviruses from infants in Sarlahi, Nepal. Journal of Medical Virology, 2019, 91, 2108-2116.	5.0	4
64	Respiratory Syncytial Virus Infection in Homeless Populations, Washington, USA. Emerging Infectious Diseases, 2019, 25, 1408-1411.	4.3	10
65	Effect of Diarrheal Illness During Pregnancy on Adverse Birth Outcomes in Nepal. Open Forum Infectious Diseases, 2019, 6, ofz011.	0.9	7
66	RSV, Antibodies and the Developing World. Pediatric Infectious Disease Journal, 2019, 38, S24-S27.	2.0	4
67	Molecular characterization of influenza viruses from women and infants in Sarlahi, Nepal. Diagnostic Microbiology and Infectious Disease, 2019, 93, 305-310.	1.8	1
68	Enterovirus Dâ€68 in children presenting for acute care in the hospital setting. Influenza and Other Respiratory Viruses, 2018, 12, 522-528.	3.4	2
69	Heterotypic Infection and Spread of Rhinovirus A, B, and C among Childcare Attendees. Journal of Infectious Diseases, 2018, 218, 848-855.	4.0	27
70	Impact of Timing of Influenza Vaccination in Pregnancy on Transplacental Antibody Transfer, Influenza Incidence, and Birth Outcomes: A Randomized Trial in Rural Nepal. Clinical Infectious Diseases, 2018, 67, 334-340.	5.8	30
71	Impact of maternal vaccination timing and influenza virus circulation on birth outcomes in rural Nepal. International Journal of Gynecology and Obstetrics, 2018, 140, 65-72.	2.3	10
72	Respiratory Virus Infection During Pregnancy: Does It Matter?. Journal of Infectious Diseases, 2018, 218, 512-515.	4.0	14

#	Article	IF	CITATIONS
73	Burden and Risk Factors for Coronavirus Infections in Infants in Rural Nepal. Clinical Infectious Diseases, 2018, 67, 1507-1514.	5.8	34
74	Maternal immunization. Birth Defects Research, 2017, 109, 379-386.	1.5	26
75	Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 981-989.	9.1	185
76	Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. Journal of Clinical Virology, 2017, 95, 90-95.	3.1	52
77	Nutritional status of infants at six months of age following maternal influenza immunization: A randomized placebo-controlled trial in rural Nepal. Vaccine, 2017, 35, 6743-6750.	3.8	4
78	Vaccines Against Respiratory Syncytial Virus: The Time Has Come. Journal of Infectious Diseases, 2017, 215, 4-7.	4.0	13
79	Human Metapneumovirus and Other Respiratory Viral Infections during Pregnancy and Birth, Nepal. Emerging Infectious Diseases, 2017, 23, .	4.3	14
80	Rhinovirus Disease in Children Seeking Care in a Tertiary Pediatric Emergency Department. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 29-38.	1.3	15
81	Respiratory syncytial virus infection in infants in rural Nepal. Journal of Infection, 2016, 73, 145-154.	3.3	15
82	Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. Influenza and Other Respiratory Viruses, 2016, 10, 205-210.	3.4	22
83	Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy. PLoS ONE, 2016, 11, e0152015.	2.5	49
84	Impact of rapid influenza PCR testing on hospitalization and antiviral use: A retrospective cohort study. Journal of Medical Virology, 2015, 87, 2021-2026.	5.0	42
85	Hemophagocytic Lymphohistiocytosis Secondary to Human Immunodeficiency Virus-Associated Histoplasmosis. Open Forum Infectious Diseases, 2015, 2, ofv140.	0.9	26
86	Molecular epidemiology of human rhinovirus infections in the pediatric emergency department. Journal of Clinical Virology, 2015, 62, 25-31.	3.1	39
87	Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 286-293.	1.3	31
88	Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh. Journal of Infectious Diseases, 2014, 210, 1582-1589.	4.0	134
89	Nosocomial Transmission of Respiratory Syncytial Virus in an Outpatient Cancer Center. Biology of Blood and Marrow Transplantation, 2014, 20, 844-851.	2.0	33
90	Maternal Immunization. Clinical Infectious Diseases, 2014, 59, 560-568.	5.8	107

#	Article	IF	CITATIONS
91	Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infectious Diseases, 2013, 13, 105.	2.9	69
92	Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine, 2013, 31, 5706-5712.	3.8	41
93	Molecular epidemiology of respiratory syncytial virus transmission in childcare. Journal of Clinical Virology, 2013, 57, 343-350.	3.1	30
94	Respiratory Syncytial Virus Disease: Prevention and Treatment. Current Topics in Microbiology and Immunology, 2013, 372, 235-258.	1.1	23
95	Morbidity and mortality among a cohort of HIV-infected adults in a programme for community home-based care, in the Kilimanjaro Region of Tanzania (2003–2005). Annals of Tropical Medicine and Parasitology, 2009, 103, 263-273.	1.6	11
96	Gender Differences in the Risk of HIV Infection among Persons Reporting Abstinence, Monogamy, and Multiple Sexual Partners in Northern Tanzania. PLoS ONE, 2008, 3, e3075.	2.5	20
97	Cost-Effectiveness of Free HIV Voluntary Counseling and Testing Through a Community-Based AIDS Service Organization in Northern Tanzania. American Journal of Public Health, 2006, 96, 114-119.	2.7	49
98	Sociodemographic and clinical characteristics of clients presenting for HIV voluntary counselling and testing in Moshi, Tanzania. International Journal of STD and AIDS, 2005, 16, 691-696.	1.1	25
99	Challenges and lessons in establishing human immune profiling cohort studies for pandemic response. Immunological Reviews, 0, , .	6.0	1